ClinicalTrials.gg
RecruitingNCT07044089Updated Sep 3, 2026

Lung Protective Ventilation and Driving Pressure Guided PEEP Titration in CABG Surgery

An observational study in Peep Titration in Lung Protective Ventilation, sponsored by Kocaeli University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Kocaeli University · Observational

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
86
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Our aim in this study is to compare fixed and individualized PEEP (driving pressure guided ) application for intraoperative lung protective ventilation in patients undergoing on-pump CABG surgery.

Researcher aimed to compare the effects of two different PEEP application methods on intraoperative hemodynamics, respiratory mechanics, and gas exchange, as well as postoperative extubation times, respiratory complications (atelectasis, need for non invasive mechanical ventilatıon, need for re-entubatıon) length of stay in the intensive care unit, and discharge times.

Read the detailed description

The primary goal of the researchers: To compare the effects of fixed PEEP versus driving pressure guided individualized PEEP in lung protective mechanical ventilation during on-pump open heart surgery effect of PaO2/ FiO2 ratio end of surgery.

The secondary goals of the researchers: To compare intraoperative hemodynamics, lung compliance and airway pressures, extubation time and respiratory complications [development of atelectasis, need for noninvasive mechanical ventilation (high-flow nasal cannula or CPAP application), need for re-intubation], length of stay in the ICU and discharge times.

02

Conditions studied

  • Peep Titration in Lung Protective Ventilation

Keywords

  • Lung Protective Ventilation
  • Fixed PEEP
  • Individualized PEEP
03

In context

Lead sponsor

Kocaeli University is the lead sponsor of 215 studies on the registry; 39 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patients who will undergo elective on-pump coronary artery bypass graft surgery under general anesthesia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled for elective on-pump coronary artery bypass graft surgery via median sternotomy
  • Patients between the ages of 18 and 70
  • ASA () physical status classification II-III

Exclusion criteria

Exclusion Criteria:

  • Patients with an below 35%
  • Patients who did not consent to participate in the study
  • Patients undergoing emergency surgery
  • Patients who are allergic to the anesthetic drugs used
  • Patients who have undergone lung resection
  • Those with a history of mechanical ventilation in the 2 months before surgery
  • Patients who have undergone total circulatory arrest and deep hypothermia
  • Patients with obstructive sleep apnea syndrome requiring long-term ventilation assistance
  • Morbid obesity (>35kg/m2)
  • Patients with hypoxemia (arterial oxygen saturation below 88% despite 100% oxygen inhalation)
  • (\<70%)
  • Patients with chronic renal failure (serum creatine>1.8 mg/dl)
  • Anemia (Hg\<10 gr/dl)
  • Patients who have had an intraaortic balloon pump placed.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
86 participants (estimated)
Patient registry
No

Groups and cohorts

  • Fixed PEEP
  • Indıvıdalızed PEEP
06

What researchers measure

Primary outcomes

  1. Effects on intraoperative oxygenation, hemodynamics, lung compliance and airway pressures

    Data will be recorded during surgery and the first 24 hours after extubation.

    Time frame: First one day

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Mar 2027, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2025
First posted
Jun 29, 2025
StartActual
Jul 23, 2025
Primary completionEst.
Mar 1, 2027
CompletionEst.
Sep 1, 2027
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07044089
Lead sponsor
Kocaeli University
Responsible party
Zeynep AÇIK (Research Assistant Doctor, Kocaeli University) — Principal investigator
First posted
Jun 29, 2025
Start date
Jul 23, 2025
Primary completion
Mar 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Sep 3, 2026

Study contacts

Zeynep Açık, MD
Contact
zeynebacik96@gmail.com
+905077367990
Tülay Çardaközü, PROFESSOR
Contact
tulayhosten@hotmail.com
+905323262342

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion